UCB

Clinicians, researchers and industry collaborate with the 100,000 Genomes Project

Friday, March 27, 2015 11:12 AM

Genomics England has announced a new collaboration as part of the 100,000 Genomes Project to accelerate the development of new diagnostics and treatments for patients. Ten pharma and biotech companies have come together to create the Genomics Expert Network for Enterprises (GENE) Consortium to oversee a year-long industry trial.

More... »


3SBio acquires Sirton Pharmaceuticals

Monday, January 26, 2015 02:25 PM

3SBio, a China-based biotechnology company, has acquired the entire share capital of Sirton Pharmaceuticals, located in Villa Guardia, Italy, from First Shanghai, a financial services provider.

More... »


Neuropore, UCB enter world-wide collaboration and agreement

Monday, January 19, 2015 12:45 PM

Neuropore Therapies, a wholly owned U.S. subsidiary of Austria-based Ever Neuro Pharma, and UCB, a Brussels, Belgium-based global biopharmaceutical company, have entered into a worldwide collaboration and agreement to develop and commercialize therapeutic products aiming at slowing the progression of Parkinson’s disease and related disorders. This includes NPT200-11, Neuropore’s novel small molecule that targets pathogenic alpha-synuclein, which currently is in preclinical development and is expected to enter clinical phase I in 2015.

More... »

UCB to sell generics business to private equity firms Advent, Avista Capital for $1.525 billion

Monday, November 10, 2014 12:26 PM

Advent International and Avista Capital Partners, two private equity firms with a strong healthcare focus, have agreed to acquire UCB’s U.S. specialty generics subsidiary, Kremers Urban Pharmaceuticals (KU). UCB is a multinational biopharmaceutical manufacturing company headquartered in Brussels, Belgium.

More... »

TransCelerate releases recommended approach for protecting personal data in Clinical Study Reports

Wednesday, September 3, 2014 08:20 AM

TransCelerate BioPharma has developed a recommended approach for protecting personal data in Clinical Study Reports (CSRs) shared with researchers, patients and others.

More... »

ABPI establishes Inward Investor Group

Wednesday, July 23, 2014 10:45 AM

The Association of the British Pharmaceutical Industry (ABPI) has established a new Inward Investor Group to demonstrate the importance of inward investment to the U.K. and the global mobility of such investment. The group also will work toward cultivating a favorable environment for pharmaceutical companies to invest in the U.K.

More... »

Seven pharma companies offer deprioritized compounds for re-purposing

Wednesday, July 23, 2014 10:15 AM

U.K. researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies.

More... »

EFPIA launches IMI2—a $4.5B public-private healthcare partnership

Wednesday, July 9, 2014 12:09 PM

EFPIA has announced the launch of IMI2, the continuation of the successful partnership of industry and public bodies to tackle health needs. IMI is a public-private partnership (PPP) between the European Commission and EFPIA, the European Federation of Pharmaceutical Industries and Associations. The first phase of IMI (2008 to 2013) was established with a budget of $2.7 billion. IMI2 has been established under the E.U. framework program Horizon 2020 with an even bigger budget of $4.5 billion—bringing together the public and private sectors in the largest healthcare PPP in Europe.

More... »

TransCelerate BioPharma launches two new global initiatives

Monday, June 16, 2014 11:47 AM

TransCelerate BioPharma is launching two new global initiatives enabled by broad participation and collaboration across the R&D community: to develop a position on the best and most efficient methods for redacting privacy information found in clinical study reports and an approach for the anonymization of patient-level data shared with the broader healthcare community; and to develop a framework for a Quality Management System (QMS) specifically for clinical research to improve the quality and efficiency of clinical trials.

More... »

Scientists invited to access UCB’s technology platform

Thursday, May 1, 2014 10:32 AM

UCB has launched its Technology Platform Access, a collaboration program for the discovery and development of novel antibodies against potential therapeutic targets.

More... »


CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs